Sickle Cell Disease (SCD) is a genetic disorder causing red blood cells to become misshaped, leading to anemia and pain. This study tests a new gene therapy, DREAM01, aiming to reduce these symptoms by using a patient's own cells, which are manipulated outside the body to carry corrected genes.

Key Points:

• The study lasts for 2 years and is for patients aged 12 to 35 with severe SCD.
• Participants must undergo a bone marrow test and agree to follow safety protocols.
• Those with a matched sibling donor or certain health conditions are not eligible.

Traditional treatments include blood transfusions and medications like hydroxyurea, but they come with risks. The only current cure is a bone marrow transplant, but it's limited to those with a compatible donor. This study offers a potential new treatment for those without a donor, reducing painful episodes and organ damage associated with SCD. Eligible participants will need to commit to frequent medical evaluations over the course of the study.